4.5 Article

Blood-Brain Barrier Permeability of Asiaticoside, Madecassoside and Asiatic Acid in Porcine Brain Endothelial Cell Model

Journal

JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 110, Issue 2, Pages 698-706

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2020.09.015

Keywords

Blood-brain barrier; Permeability; In vitro model; Endothelial; Natural products; Central nervous system

Funding

  1. NRGS NKEA EPP from the Ministry of Agriculture & Agro-Based Industry Malaysia [304/CDADAH/650745/K123]
  2. Ministry of Higher Education Malaysia under the HICoE Programme [311.CDADAH.4401009]

Ask authors/readers for more resources

Centella asiatica has neurotherapeutic potentials and its compounds show high capability to cross the blood-brain barrier, suggesting a promising development as therapeutics for the treatment of neurodegenerative diseases.
Neurotherapeutic potentials of Centella asiatica and its reputation to boost memory, prevent cognitive deficits and improve brain functions are widely acknowledged. The plant's bioactive compounds, i.e. asiaticoside, madecassoside and asiatic acid were reported to have central nervous system (CNS) actions, particularly in protecting the brain against neurodegenerative disorders. Hence, it is important for these compounds to cross the blood-brain barrier (BBB) to be clinically effective therapeutics. This study aimed to explore the capability of asiaticoside, madecassoside and asiatic acid to cross the BBB using in vitro BBB model from primary porcine brain endothelial cells (PBECs). Our findings showed that asiaticoside, madecassoside and asiatic acid are highly BBB permeable with apparent permeability (P-app) of 70.61 +/- 6.60, 53.31 +/- 12.55 and 50.94 +/- 10.91 x 10(-6) cm/s respectively. No evidence of cytotoxicity and tight junction disruption of the PBECs were observed in the presence of these compounds. Asiatic acid showed cytoprotective effect towards the PBECs against oxidative stress. This study reported for the first time that Centella asiatica compounds demonstrated high capability to cross the BBB, comparable to central nervous system drugs, and therefore warrant further development as therapeutics for the treatment of neurodegenerative diseases. (c) 2020 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available